Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

Dna testing stocks

Ready to invest in the genetic testing industry? Consider these 4 stocks.

DNA testing is getting more popular, and interest in investing in genetics is trending up as well. While a lot of the most popular names in home DNA test kits, like 23andme and Ancestry, aren't yet publicly traded, there are still plenty of companies that let you invest on the trend. There are also new IPOs in this field, with via a merger with VG Acquisition (VGAC).

The best genetic testing stocks depend on your portfolio and investment goals — while volatility can be ideal for day traders, long-term investors will want to look to stocks with steadier gains over time.

How to buy dna testing stocks

Sign up with an online broker or platform to invest in one of more of these dna testing stocks.

  1. Compare share trading platforms. Use our comparison table to narrow down top brokers by fees and bonuses.
  2. Open and fund your brokerage account. You’ll need personal and financial details, like your contact and bank information.
  3. Search for the stock you're interested in. Find the stock by name or ticker symbol, like NTRA or GENE.
  4. Decide on how many to buy. Some brokers will allow you to purchase fractional shares, while others require you to purchase whole shares.
  5. Choose an order type. Invest in the dna testing stocks now with a market order or use a limit order to delay your purchase until the stock reaches your desired price.
  6. Buy the stock. Tap or click the Buy button on your brokerage account. Once you’ve invested in the genetic testing industry, track how your stock performs to decide when it’s time to sell.

Take a deeper dive into dna testing stocks

We round up a selection of stocks in or related to the genetic testing industry, weighting the list more heavily towards popular mid- and large-cap US stocks.

1. Natera (NTRA)

Natera, Inc. , a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.

Natera stock opened the day at $117.90 after a previous close of $117.29. The latest price was $120.94 (25 minute delay). Natera is listed on the NASDAQ, has a trailing 12-month revenue of around USD449.3 million and employs 1,815 staff.

  • Market capitalization: $9,759,145,984
  • PEG ratio: 0

Back to top


2. Genetic Technologies (GENE)

Genetic Technologies Limited, a molecular diagnostics company, provides predictive testing and assessment tools to help physicians manage women's health in Australia and the United States. The company's lead product is the BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons.

Genetic Technologies stock opened the day at $4.05 after a previous close of $4.05. The latest price was $4.18 (25 minute delay). Genetic Technologies is listed on the NASDAQ and has a trailing 12-month revenue of around USD$25,714.

  • Market capitalization: $53,212,336
  • PEG ratio: 0

Back to top


3. VG Acquisition (VGAC)

VG Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses.

VG Acquisition stock opened the day at $10.99 after a previous close of $10.99. The latest price was $10.99 (25 minute delay). VG Acquisition is listed on the NYSE.

  • Market capitalization: $698,619,968

Back to top


4. Sangamo Therapeutics (SGMO)

Sangamo Therapeutics, Inc. , a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucleases, which are proteins used in modifying DNA sequences by adding or knocking out specific genes or genome editing; and ZFP transcription factors proteins used in increasing or decreasing gene expression.

Sangamo Therapeutics stock opened the day at $12.01 after a previous close of $12.01. The latest price was $11.71 (25 minute delay). Sangamo Therapeutics is listed on the NASDAQ, has a trailing 12-month revenue of around USD$131.4 million and employs 413 staff.

  • Market capitalization: $1,398,523,264
  • PEG ratio: 0

Back to top

Compare trading platforms

Compare online trading platforms by fees, asset types and bonuses to find the best for your investment in dna testing stocks.
Name Product Asset types Signup bonus
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Robinhood
Stocks, Options, ETFs
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Public
Stocks, ETFs
Download and sign up with Public.com; approved accounts receive a free stock slice worth up to $70, selected from 9 popular stocks.
Open an account
Commission-free trading in stocks and ETFs with a social networking twist.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
N/A
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
Webull
Stocks, Options, ETFs
Get one free stock valued between $3.00 and $300 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
TD Ameritrade
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
TD Ameritrade features $0 commission for online stock trades. Online options fees are $0.65/contract.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Bottom line

While it’s possible to turn a profit investing in dna testing stocks, keep in mind that — like any investment — dna testing stocks are not immune to risk. These stocks are subject to fluctuating conditions — both in the market and in the genetic testing industry, so carefully vet your picks before you invest. And if you’re new to investing, or if it’s been awhile since you’ve taken a critical look at your investing accounts, compare brokers to make sure you’re getting the best features in your trading account.

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site